HomeCompareGILD vs ZBH

GILD vs ZBH: Dividend Comparison 2026

GILD yields 2.34% · ZBH yields 1.08%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GILD wins by $7.9K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
ZBH
ZBH
● Live price
1.08%
Share price
$88.62
Annual div
$0.96
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$118.64
Full ZBH calculator →

Portfolio growth — GILD vs ZBH

📍 GILD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDZBH
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + ZBH cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
ZBH pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
ZBH
Annual income on $10K today (after 15% tax)
$92.08/yr
After 10yr DRIP, annual income (after tax)
$100.84/yr
At 15% tax rate, GILD beats the other by $1,271.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + ZBH for your $10,000?

GILD: 50%ZBH: 50%
100% ZBH50/50100% GILD
Portfolio after 10yr
$25.2K
Annual income
$866.77/yr
Blended yield
3.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
ZBH
Analyst Ratings
17
Buy
21
Hold
3
Sell
Consensus: Hold
Price Target
$105.60
+19.2% upside vs current
Range: $89.00 — $122.00
Altman Z
1.7
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
ZBH buys
0
No recent congressional trades found for GILD or ZBH in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDZBH
Forward yield2.34%1.08%
Annual dividend / share$3.19$0.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%0.2%
Portfolio after 10y$29.1K$21.2K
Annual income after 10y$1,614.90$118.64
Total dividends collected$7.6K$1.1K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyHold
Analyst price target$158.71$105.60

Year-by-year: GILD vs ZBH ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrZBH PortfolioZBH Income/yrGap
1← crossover$10,974$274.45$10,809$108.54+$165.00GILD
2$12,073$330.19$11,675$109.86+$398.00GILD
3$13,316$398.20$12,603$111.13+$713.00GILD
4$14,730$481.49$13,598$112.34+$1.1KGILD
5$16,345$583.87$14,663$113.51+$1.7KGILD
6$18,199$710.26$15,804$114.62+$2.4KGILD
7$20,340$866.96$17,026$115.69+$3.3KGILD
8$22,826$1,062.22$18,335$116.71+$4.5KGILD
9$25,731$1,306.80$19,736$117.70+$6.0KGILD
10$29,147$1,614.90$21,236$118.64+$7.9KGILD

GILD vs ZBH: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

ZBHHealthcare

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Full ZBH Calculator →
📬

Get this GILD vs ZBH comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.